Oncology
Sanofi’s Sarclisa accepted for FDA priority review
May 29, 2024Medical Communications FDA, Oncology, Sanofim, Sarclisa, multiple myeloma, priority review
Sanofi has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …
Merck shares data from phase 3 trial of Keytruda for TNBC treatment
May 29, 2024Medical Communications Merck, Oncology, breast cancer, clinical trial, keytruda
Merck, known as MSD outside of the US and Canada, has announced results from the phase 3 KEYNOTE-522 trial, which …
AstraZeneca shares results from phase 3 TROPION-Lung01 trial
May 28, 2024Medical Communications AstraZeneca, Daiichi Sankyo, NSCLC, Oncology, clinical trial, datopotamab deruxtecan
AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd). The survival …
Nona Biosciences announced agreement with AstraZeneca for tumour targeted therapies
May 24, 2024Research and Development AstraZeneca, Cancer, Oncology, nona biosciences, targeted therapies
Nona Biosciences and AstraZeneca have announced that the two companies have entered into a license agreement for preclinical monoclonal antibodies, …
AstraZeneca to build $1.5bn ADC facility in Singapore
May 20, 2024Manufacturing and Production ADCs, AstraZeneca, Oncology, antibody drug conjugate, manufacturing
AstraZeneca has announced that it intends to build a $1.5bn manufacturing facility in Singapore, Singapore, for antibody drug conjugates (ADCs), …
FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer
May 17, 2024Medical Communications Amgen, FDA, Oncology, lung cancer
Amgen has announced that the US Food and Drug Administration (FDA) has approved Imdelltra (tarlatamab-dlle) for the treatment of adult …
FDA approves Roche’s HPV self-collection screening option
May 15, 2024Medical Communications FDA, HPV, Oncology, Roche, cervical cancer
Roche has announced that the US Food and Drug Administration (FDA) has approved its human papillomavirus (HPV) self-collection solution. This …
AstraZeneca shares positive interim results from phase 3 lymphoma trial
May 3, 2024Medical Communications AstraZeneca, Calquence, Oncology, clinical trial, lymphoma
AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 trial, which assessed Calquence (acalabrutinib) …
Merck shares data from phase 3 trial of Keytruda for gastric cancers
May 2, 2024Research and Development Gastric, MSD, Merck, Oncology, keytruda
Merck, known as MSD outside of the US and Canada, has announced data from the phase 3 KEYNOTE-811 trial which …
J&J gains positive CHMP opinion for Rybrevant for treatment of lung cancer
April 29, 2024Medical Communications CHMP, EMA, J&J, Oncology, Rybrevant, lung cancer
Janssen, a Johnson & Johnson (J&J) company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of …
Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement
April 25, 2024Research and Development Oncology, Ono Pharmaceutical, Prism BioLab, research and licensing agreement
Prism BioLab has announced that it has entered into a target-exclusive research and licensing agreement with Ono Pharmaceutical. Under the …
GSK’s Jemperli accepted for FDA review for endometrial cancer treatment
April 24, 2024Medical Communications FDA, GSK, Oncology, endometrial cancer, sBLA
GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for …
FDA approves ImmunityBio’s Anktiva bladder cancer treatment
April 23, 2024Medical Communications Anktiva, FDA, ImmunityBio, Oncology, bladder cancer
ImmunityBio has announced that the US Food and Drug Administration (FDA) has approved Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus …
Roche’s Alecensa approved by FDA as lung cancer treatment
April 19, 2024Medical Communications FDA, Oncology, Roche, lung cancer
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) for the adjuvant treatment following …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
April 15, 2024Research and Development Columbi, Genentech, Oncology, Roche, clinical trial, lymphoma
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has met its primary endpoint of …
Latest content
FibroFind appoints Lee Borthwick as CEO
